statnews.com·Feb 23, 2026
Novo Nordisk's next-generation obesity drug has underperformed in a comparison study against Eli Lilly's treatment, as reported in a biotech news roundup by The Readout.
Gilead's acquisition of Arcellx for nearly $8 billion signals a significant investment in CAR-T therapies, specifically targeting multiple myeloma. This move highlights the growing interest in cell therapy as a promising area in biotech, presenting potential opportunities for stakeholders in healthtech and biotech sectors to explore partnerships or investments in innovative therapeutic approaches similar to CAR-T.